熱門資訊> 正文

Pharvaris GAAP每股收益为-0.60欧元

2025-11-12 22:42

Pharvaris N.V.(PHVS) 0
摩根士丹利(MS) 0

Pharvaris press release (PHVS): Q3 GAAP EPS of -€0.60.
Cash and cash equivalents were €329 million as of September 30, 2025, compared to €281 million for December 31, 2024.
Research and Development (R&D) Expenses. R&D expenses were €29.8 million for the quarter ended September 30, 2025, compared to €25.8 million for the quarter ended September 30, 2024.
General and Administrative (G&A) Expenses. G&A expenses were €9.8 million for the quarter ended September 30, 2025, compared to €12.1 million for the quarter ended September 30, 2024.

More on Pharvaris

Pharvaris N.V. (PHVS) Presents at ACAAI 2025 Annual Scientific Meeting - Slideshow
Pharvaris N.V. (PHVS) Presents at 2025 HAE International (HAEi) Regional Conference EMEA - Slideshow
Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Seeking Alpha’s Quant Rating on Pharvaris
Historical earnings data for Pharvaris

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。